肿瘤坏死因子α预处理脐血间充质干细胞移植治疗心肌梗死

文章快速阅读：文题释义： 心肌缺血：是指心脏的血液灌注减少，导致心脏的供氧减少，心肌能量代谢不正常，不能支持心脏正常工作的一种病理状态。血压降低、主动脉供血减少、冠状动脉阻塞，可直接导致心脏供血减少；心瓣膜病、血黏度变化、心肌本身病变也会使心脏供血减少，心肌缺血对心脏和全身可能带来许多危害。目前针对这种疾病治疗主要的作用机制包括：降低心肌耗氧量，提高耐缺氧能力，清除自由基、抗氧化作用，调节血栓素A 2/前列环素，调节一氧化氮细胞内皮素1、抑制肿瘤坏死因子α和白细胞介素的释放等。 脐血间充质干细胞移植：移植成功最主要的障碍为移植后只有少量脐血间充质干细胞移植至心肌内并存活，因此提高脐血间充质干细胞向心肌内迁移和定植及其存活率对治疗效果具有重要意义。移植前对脐血间充质干细胞进行肿瘤坏死因子α预处理，发现肿瘤坏死因子α预处理胎儿脐血间充质干细胞移植治疗大白兔缺血性心脏病可以改善心脏功能、减少心肌梗死面积和心肌纤维化面积。 摘要 背景：心肌缺血损伤后，心肌细胞释放大量炎症递质作为对心肌损伤的应答，梗死及缺血区的炎症因子有助于心肌组织对损伤的修复和适应。 目的：探讨肿瘤坏死因子α预处理脐血间充质干细胞移植治疗对心肌梗死兔心功能的效果。 方法：将36只大白兔随机等分为4组，假手术组、模型组、无肿瘤坏死因子α组和肿瘤坏死因子α组，后3组建立心肌梗死模型。造模后24 h，模型组、无肿瘤坏死因子α组和肿瘤坏死因子α组分别在梗死中心区及边缘注射PBS、未经肿瘤坏死因子α预处理的脐血间充质干细胞及经肿瘤坏死因子α预处理的脐血间充质干细胞。 结果与结论：与模型组相比，肿瘤坏死因子α组和无肿瘤坏死因子α组兔心脏功能明显恢复，心肌梗死面积及心肌纤维化面积明显减小；且肿瘤坏死因子α组的效果优于无肿瘤坏死因子α组。表明肿瘤坏死因子α预处理胎儿脐血间充质干细胞移植能有效治疗心肌梗死。 中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程 ORCID: 0000-0002-4513-3726(王巍)

Tumor necrosis factor-alpha pretreated umbilical cord blood mesenchymal stem cell transplantation for treatment of myocardial infarction

BACKGROUND:A large amount of inflammatory mediators from myocardial cells are secreted in  response to myocardial injury after myocardial ischemia. Moreover, inflammatory cytokines in infarction and ischemia regions contribute to myocardial tissue repair and adaptation. OBJECTIVE:To investigate the effect of tumor necrosis factor-α (TNF-α) pretreatment on cardiac function of myocardial infarction rabbits undergoing umbilical cord blood mesenchymal stem cell transplantation. METHODS:Thirty-six white rabbits were equally randomized into sham, model, non-TNF-α, and TNF-α groups. Animal models of myocardial infarction were made in the latter three groups. Twenty-four hours after modeling, PBS, umbilical cord blood mesenchymal stem cells pretreated with or without TNF-α were injected at infarct center and border, respectively, in the model, TNF-α and non-TNF-α groups. RESULTS AND CONCLUSION:Model rabbits in the TNF-α and non-TNF-α groups showed better cardiac function and lower size of myocardial infarction and fibrosis than those in the model group. Compared with the non-TNF-α group, moreover, the TNF-α group showed better outcomes in these indicators. These findings indicate that TNF-α pretreatment can markedly improve the therapeutic efficacy of umbilical cord blood mesenchymal stem cell transplantation on myocardial infarction.